A viable therapeutic strategy utilizing immunotherapy and MEK inhibitors has been suggested by the preclinical efficacy of trametinib as well as immunomodulatory antibodies in KRAS/p53-mutant lung cancer [107]. This evidence concerns the gene KRAS and lung carcinoma.